Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, shared a post on X/Twitter:
“Excellent guidelines from the British Society of Hematology highlighting how there is insufficient evidence to treat high-risk SMM with len.
I would go one step further and say many enrolling trials can result in great harm to these folks.”
Source: Manni Mohyuddin/X